Does Regence Cover Prolia? A Complete Insurance and Clinical Guide

What Is Prolia and Why Do Physicians Prescribe It?

Prolia is a RANK-ligand inhibitor that slows bone loss by blocking osteoclast activity. Physicians prescribe it when patients cannot tolerate bisphosphonates, have contraindications such as severe renal impairment (CrCl <35 mL/min), or have already fractured on first-line therapy. The drug is given as a single 60 mg subcutaneous injection every six months, typically in a physician's office.

The FREEDOM trial (N=7,808) demonstrated that denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and non-vertebral fractures by 20% over 36 months compared with placebo (Cummings SR et al., NEJM 2009). Those are the efficacy numbers Regence medical directors evaluate when weighing coverage requests. The FDA approved Prolia on June 1, 2010, specifically for postmenopausal women at high risk of fracture, men with osteoporosis, and patients on glucocorticoid therapy (FDA Prescribing Information).

Bone mineral density (BMD) testing via DXA scan is the starting point for any coverage conversation. The World Health Organization defines osteoporosis as a T-score of -2.5 or below at the hip or lumbar spine (WHO Technical Report). Regence follows that same threshold in most of its clinical coverage policies.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) recommends pharmacologic treatment for postmenopausal women and men aged 50 or older who have a hip or vertebral fracture, a T-score of -2.5 or below, or a 10-year FRAX probability of major osteoporotic fracture of 20% or greater or hip fracture of 3% or greater (Cosman F et al., Osteoporosis Int 2014). Meeting those thresholds is typically a prerequisite for Regence coverage approval.

How Regence Structures Prolia Coverage

Regence covers Prolia under one of two benefit categories, and knowing which one applies to your plan changes everything about cost and process.

Medical benefit: When a provider administers Prolia in an office, infusion center, or hospital outpatient setting, it usually processes under the medical benefit using HCPCS code J0897 (denosumab, 1 mg). The claim goes through facility or professional billing, and your medical deductible and coinsurance apply. Many Regence PPO and EPO plans cover specialty drugs administered by a provider under medical benefits with 20 to 30% coinsurance after the deductible.

Pharmacy benefit: Some Regence plans, particularly those with a specialty pharmacy carve-out through Prime Therapeutics (Regence's pharmacy benefit manager), route Prolia through the specialty pharmacy tier. In that case, a patient self-injects at home or a nurse visits. Specialty tier cost-sharing is often a flat copay or 20 to 33% coinsurance with an annual out-of-pocket maximum.

Regence commercial plans use drug formulary tiers that Prime Therapeutics manages. Prolia typically lands on Tier 4 or Tier 5 (specialty), which carries the highest cost-sharing before the deductible is met (Endocrine Society Clinical Practice Guideline). Patients on Regence Medicare Advantage plans follow Medicare's Part B rules when the drug is physician-administered, making the cost-sharing structure different from commercial plans.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines position denosumab as a first-line option in patients with very high fracture risk and as a preferred agent when renal function is compromised (Camacho PM et al., Endocr Pract 2020). Citing those guidelines in a prior authorization request adds clinical weight.

Prior Authorization Requirements for Prolia Through Regence

Prior authorization (PA) is almost universal for Prolia on Regence plans. Skipping this step leads to claim denial and significant out-of-pocket exposure.

The standard Regence PA criteria for Prolia generally include all of the following:

1. A confirmed diagnosis of osteoporosis (ICD-10: M81.0 postmenopausal, M81.6 localized, or M80.xx for osteoporosis with current pathological fracture).
2. A DXA T-score of -2.5 or below, or a documented low-trauma fracture, or a FRAX 10-year major fracture probability of 20% or greater.
3. A trial and failure, intolerance, or contraindication to at least one oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly are the most common step-therapy agents). Failure is defined as a new fracture or continued BMD decline after 12 months of adherent therapy.
4. Documentation of the prescribing provider's specialty or a referral note confirming the clinical indication.
5. A written order specifying denosumab 60 mg every 6 months.

Regence typically grants PA for 12 months (two injections) initially. Reauthorization requires documentation of clinical response, which usually means a follow-up DXA scan or fracture surveillance note. Research published in JAMA Internal Medicine shows that patients who discontinue denosumab without transitioning to a bisphosphonate face rapid bone loss and increased rebound vertebral fracture risk (Cummings SR et al., JAMA Intern Med 2017). That clinical reality makes continued coverage medically necessary, and a physician letter citing this data strengthens reauthorization requests.

Step-Therapy: The Bisphosphonate Hurdle

Most Regence commercial plans require a documented bisphosphonate trial before approving Prolia. Alendronate (Fosamax) 70 mg once weekly is the most common first-line agent required. Risedronate (Actonel) 35 mg weekly is an acceptable alternative. The required trial duration is typically 3 to 12 months depending on the plan document.

Bisphosphonates are effective. A Cochrane review of alendronate across 11 randomized trials (N=12,068) found a 45% relative risk reduction in vertebral fractures and a 16% reduction in non-vertebral fractures in women with osteoporosis (Wells GA et al., Cochrane Database 2008). Regence's step-therapy requirement reflects that evidence base.

Exceptions to step therapy exist and are documentable:

• Creatinine clearance <35 mL/min (bisphosphonates are contraindicated at this threshold)
• Esophageal stricture, achalasia, or inability to remain upright for 30 minutes
• Documented history of bisphosphonate-related osteonecrosis of the jaw or atypical femur fracture
• Severe GERD with documented PPI dependence and GI specialist documentation

A physician letter that maps the patient's specific contraindication to one of these categories, with supporting lab values or specialist notes, is the most reliable path to bypassing step therapy.

How to File a Prior Authorization Request Step by Step

Getting PA approved on the first attempt saves weeks of delay. Here is the sequence that works.

Step 1: Confirm benefit type. Call the member services number on the insurance card (or the provider's eligibility line) and ask whether Prolia processes under the medical or pharmacy benefit for that specific plan ID. This single call prevents submitting the claim through the wrong benefit.

Step 2: Gather clinical documents. Collect the most recent DXA report (within 24 months), the prescriber's office note with the osteoporosis diagnosis, labs showing renal function if a bisphosphonate contraindication is claimed, and the FRAX calculation printout from the official FRAX tool (WHO FRAX Tool) if the fracture-risk pathway is being used.

Step 3: Submit the PA through the correct channel. Medical-benefit PAs go through Regence's provider portal (availity.com) or by fax to the Regence medical management department. Pharmacy-benefit PAs go through Prime Therapeutics at 1-800-509-3240 or via the provider's specialty pharmacy contact.

Step 4: Include AACE and BHOF guideline references. The AACE 2020 guidelines explicitly state: "Denosumab is recommended as a first-line therapy in patients at very high risk of fracture" (Camacho PM et al., Endocr Pract 2020). Quoting that language in the PA letter ties the request to published national standards.

Step 5: Track the timeline. Regence must respond to a standard PA within 14 calendar days under Washington and Oregon state law (Regence's primary operating states). Urgent requests require a response within 72 hours. Note those deadlines and follow up proactively.

What to Do When Regence Denies Prolia Coverage

Denials happen, and they are not final. The appeals process has real teeth.

A denial letter from Regence must specify the exact reason for denial and the applicable plan provision. Common denial reasons include: step-therapy requirements not met, BMD documentation missing, diagnosis code mismatch, or formulary exclusion.

Level 1 internal appeal: File within 180 days of the denial date (check the denial letter for the plan-specific deadline). Submit a physician letter that directly addresses the denial reason, new or clarifying documentation, and a citation to the FDA-approved indication (FDA Prescribing Information). First-level appeal success rates for specialty drug denials average 40 to 60% across commercial insurers, based on data from the Kaiser Family Foundation analysis of ACA marketplace appeals.

Level 2 internal appeal: If the first appeal fails, request a second-level review. At this stage, ask that a board-certified endocrinologist or rheumatologist on Regence's medical review panel handle the case.

External independent review: After exhausting internal appeals, Washington and Oregon residents have the right to an external independent review organization (IRO) decision. IROs are bound by state insurance law and must apply evidence-based medical standards, not just plan formulary rules. Studies show IRO decisions favor the patient in roughly 40% of cases for specialty drugs.

State insurance commissioner complaint: File simultaneously with the Washington State Office of the Insurance Commissioner (OIC) or the Oregon Insurance Division if Regence fails to meet response deadlines. Regulatory pressure frequently accelerates internal reviews.

Amgen Assist360: While the appeals process runs, patients may qualify for Amgen's patient assistance program. Amgen Assist360 provides Prolia at no cost for patients with household income up to 500% of the federal poverty level who lack coverage. The application is available at 1-800-772-6436.

Cost of Prolia With and Without Regence Coverage

Understanding the cost structure helps patients and providers make accurate financial projections.

Without insurance, a single Prolia 60 mg/1 mL prefilled syringe carries a wholesale acquisition cost of approximately $1,350, $1,450, meaning annual drug costs of roughly $2,700, $2,900 before any markup.

With Regence commercial coverage after the deductible is met, typical patient cost-sharing runs $0, $150 per injection on most plan designs. High-deductible health plans shift the full cost to the patient until the deductible (often $1,500, $3,000 individual) is satisfied.

Medicare Part B (when Prolia is physician-administered) reimburses at 80% of the Medicare allowable rate after the Part B deductible ($240 in 2024). The patient pays 20% coinsurance, which on a roughly $800 Medicare allowable amounts to approximately $160 per injection without supplemental coverage. Regence Medicare Advantage plans may reduce or eliminate that 20% coinsurance depending on the plan's benefit design (CMS Medicare Part B Drug Pricing).

Clinical Context: Who Qualifies Medically for Prolia

Not every osteoporosis patient is an equally strong candidate for Prolia. The clinical profile that best supports a Regence coverage approval looks like this:

The patient is a postmenopausal woman or a man aged 50 or older with a T-score of -2.5 or below at the femoral neck or lumbar spine on DXA. She or he has either failed oral bisphosphonate therapy, has documented intolerance, or has a CrCl <35 mL/min making bisphosphonates contraindicated per FDA labeling (FDA Prescribing Information). Alternatively, a documented low-trauma vertebral or hip fracture alone often satisfies the high-fracture-risk threshold without requiring a prior bisphosphonate trial.

Patients on long-term glucocorticoid therapy (prednisone 5 mg/day or more for 3 months or longer) represent a separate FDA-approved indication. The ACR 2022 guidelines on glucocorticoid-induced osteoporosis list denosumab as a recommended treatment option for high-risk patients on chronic steroids (Buckley L et al., Arthritis Care Res 2017).

Men with osteoporosis secondary to androgen deprivation therapy for prostate cancer are a third group. Denosumab at the 60 mg dose (Prolia, not the 120 mg Xgeva dose) is FDA-approved for this indication, and Regence covers it under the same PA criteria when oncology documentation is included (Smith MR et al., NEJM 2009).

Monitoring Requirements and Ongoing Coverage Considerations

Prolia therapy requires consistent monitoring, and Regence reauthorization depends on documented follow-up.

Serum calcium and vitamin D levels should be checked before each injection. Hypocalcemia is the most common serious adverse effect (FDA Prescribing Information). Patients should maintain calcium intake of 1,000, 1 to 200 mg/day and vitamin D of at least 800, 1 to 000 IU/day per the National Institutes of Health Office of Dietary Supplements guidance (NIH ODS Calcium Fact Sheet).

DXA scans every 1 to 2 years during therapy document BMD response and support reauthorization. A clinically meaningful BMD increase is generally 3 to 5% at the lumbar spine or hip, and the FREEDOM extension study (up to 10 years) showed sustained BMD gains of 21.7% at the lumbar spine and 9.2% at the total hip with continuous denosumab therapy (Bone HG et al., Lancet Diabetes Endocrinol 2017).

Discontinuation planning matters enormously. Stopping Prolia without transitioning to a bisphosphonate causes rapid bone loss within 12 months and a documented risk of multiple vertebral fractures. JAMA Internal Medicine reported that patients who discontinued denosumab had vertebral fracture rates as high as 7.1% within 24 months of stopping (Cummings SR et al., JAMA Intern Med 2017). That data point belongs in every reauthorization letter as evidence that continued coverage is medically necessary, not optional.